FPF
ADMS

FNY Partners Fund’s Adamas Pharmaceuticals ADMS Stock Holding History

FNY Partners Fund’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10,913
Closed -$231K – 659
2017
Q3 		$231K Buy
+10,913
New +$200K 0.04% 162

Other funds holding ADMS

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

FNY Partners Fund's ADMS Position: Q4 2017 in Review

FNY Partners Fund sold out of Adamas Pharmaceuticals (ADMS) in Q4 2017, closing a stake of 10,913 shares — an estimated $231K sold.

FNY Partners Fund first reported a position in ADMS in Q3 2017 and held it in 1 quarter. The position peaked at $231K in Q3 2017. 117 funds tracked by Wall St. Rank hold ADMS as of Q4 2017.

  • FNY Partners Fund reported no remaining Adamas Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • FNY Partners Fund sold 10,913 Adamas Pharmaceuticals shares in Q4 2017, an estimated $231K.
  • FNY Partners Fund first reported a position in Adamas Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • FNY Partners Fund's Adamas Pharmaceuticals position peaked at $231K in Q3 2017.
  • 117 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2017.

Based on FNY Partners Fund's 13F filing for Q4 2017, filed 24 Jan 2018.